Neurocrine Biosciences (NBIX) Stock Price, Quote, News & History | Benzinga

Neurocrine Biosciences Inc (NBIX) Stock Price, Quote, News & History

NBIXNASDAQ

Trade with Public

Trade with Public

$152.72

1.901.26%

Last update: Aug 14, 4:00 PM

$152.72

1.901.26%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$149.72

Close

$152.72

Volume / Avg.

1.31M / 1.27M

Day Range

$148.78 - $153.42

52 Wk Range

122.14 - 186.12

Market Cap

$15.36B

P/E Ratio

22.05

Dividend Yield

-

Exchange

NASDAQ

RSI

35

Short Interest

5.69%

Days to Cover

3.01

Recent Neurocrine Biosciences, Inc. News

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.

Vandana Singh

Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets under management climbed to $476 million.

Chandrima Sanyal

Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.

Avi Kapoor

Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market

Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.

Vandana Singh

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Neurocrine shares fell 8% after mixed earnings, strong Ingrezza sales, and a 2026 outlook that met expectations. Analysts see long-term upside despite short-term pressure.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

898.10M

Investing Cash Flow (TTM)

-891.20M

Financing Cash Flow (TTM)

60.20M

Free Cash Flow (TTM)

870.40M

Capital Expenditure (TTM)

-27.70M

Net Change in Cash (TTM)

67.10M

Analyst Trends and Forecast

6

1

Apr

9

1

May

1

Jun

12

2

Jul

3

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$15.34B

PE Ratio (TTM)

22.05

PE Ratio (FWD)

22.27

PEG Ratio (TTM)

0.45

PS Ratio (TTM)

4.63

PB Ratio (TTM)

4.15

Earnings Yield % (TTM)

4.54%

Earnings Yield % (FWD)

4.49%

EV / EBITDA (TTM)

16.65

Price / EBITDA (TTM)

16.94

Price / Free Cash Flow (TTM)

17.93

Book Value / Share

$36.34

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$600.00M

Total Cash

$332.40M

Debt to Equity

0.11

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

-$600.00M

Key Statistics

Open

$149.72

Close

$152.72

Volume / Avg.

1.31M / 1.27M

Day Range

$148.78 - $153.42

52 Wk Range

122.14 - 186.12

Market Cap

$15.36B

P/E Ratio

22.05

Dividend Yield

-

Exchange

NASDAQ

RSI

35

Short Interest

5.69%

Days to Cover

3.01

About

Sector

Health Care

Industry

Biotechnology

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions su...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Neurocrine Biosciences (NBIX) stock?

A

You can purchase shares of Neurocrine Biosciences (NASDAQ:NBIX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Neurocrine Biosciences (NBIX) competitors?

A

Other companies in Neurocrine Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Neurocrine Biosciences (NBIX) stock?

A

Neurocrine Biosciences has a consensus price target of $198.38.

Q

What is the current price for Neurocrine Biosciences (NBIX)?

A

The stock price for Neurocrine Biosciences (NASDAQ: NBIX) is $152.72 last updated August 14, 2026 at 4:00 PM EDT.

Q

Does Neurocrine Biosciences (NBIX) pay a dividend?

A

There are no upcoming dividends for Neurocrine Biosciences.

Q

When is Neurocrine Biosciences (NASDAQ:NBIX) reporting earnings?

A

Neurocrine Biosciences does not have any upcoming earnings scheduled.

Q

Is Neurocrine Biosciences (NBIX) going to split?

A

There is no upcoming split for Neurocrine Biosciences.

Q

What sector and industry does Neurocrine Biosciences (NBIX) operate in?

A

Neurocrine Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.